$INTT

INTEST CORP (INTT): Entry into a Material Definitive Agreement

INTEST CORP (INTT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement The information set forth in Item 2.03 of this Current Report on Form 8-K (this “Current Report”) is incorporated herein by reference. Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance

Original reporting
Published Aug 17, 2026, 8:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$INTT
Neutral
medium confidence
Mentioned
$INTT
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INTTNeutralMed
01

Why it matters

The amendment extends the term loan draw period from Aug 28, 2026 to Aug 28, 2028, while keeping term loan maturity at May 2, 2031, and ratifies existing liens and default provisions.

02

Market read

For traders, the key takeaway is incremental liquidity runway via an extended draw period, offset by continued secured obligations and covenant/default language.

03

What to watch

The excerpt does not show whether interest rate, covenants, collateral, or borrowing limits changed; those details could materially alter risk and equity valuation.

Relevance 6/10Novelty 6/10Timing: filed after-hours on Aug 17, 2026

Background

The company previously had a loan and security agreement dated Oct 15, 2021, amended multiple times through Apr 30, 2026.

Company-level read

Ticker impact

$INTTNeutralMedium confidence
Context

INTEST CORP entered an eighth amendment to its M&T Bank loan, extending the term loan draw period to Aug 28, 2028.

Expected impact

Likely modest, liquidity-supportive reaction, with follow-through dependent on any disclosed covenant or pricing changes not shown in the excerpt.

Evidence & confidence

The newest concrete fact is the extension of the draw period; the excerpt does not provide pricing, covenant tightening, or amounts, so the market impact is likely limited and sentiment-neutral.

Market effects

Credit-market conditions and lender risk appetite may be reflected in how often small-cap borrowers extend secured facilities.

No clear regional spillover indicated.

No direct global linkage beyond general credit availability.

Counterpoint

An extension can still signal stress if it is granted only after renegotiation, potentially implying tighter terms or higher risk than before.

Key entities

  • INTT

    Borrower under the amended and restated loan and security agreement.

  • M&T Bank

    Counterparty bank entering the eighth amendment.

Related articles

$INTTMedAI 8/10

InTest (INTT) Q2 2026 Earnings Call Transcript

InTest (INTT) reported Q2 2026 revenue of $35.3M, up 25.5% YoY, with semi orders $12.0M (+64% YoY) and backlog $45.4M (+19.8% YoY). Full-year guidance raised to $135M-$140M. Gross margin was 40.5% and adjusted EBITDA $2.2M. CFO cited a material weakness at Alfamation.

$INTTMed

INTEST CORP (INTT): Results of Operations and Financial Condition

INTEST CORP (INTT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE 804 EAST GATE DRIVE, SUITE 200, MOUNT LAUREL, NJ 08054 FOR IMMEDIATE RELEASE InTest Reports Strong Second Quarter 2026 Revenue of $35.3 Million EPS of $0.04 and Adjusted EPS (Non-GAAP) of $0.09 • Second quarter revenue up 25.5% year-over-year, driven lar

$INTTMed

Why is inTest stock climbing today?

inTest Corp (INTT) shares rose 1.7% in pre-open trading after Northland upgraded the stock to “outperform” from “market perform” and set a $15.00 price target. Northland cited inTest’s preliminary Q2 2026 revenue estimate of about $35M and raised full-year 2026 revenue guidance to $135M-$140M, while noting a planned 220 bps gross margin reduction.

$INTTMed

INTEST CORP (INTT): Results of Operations and Financial Condition

INTEST CORP (INTT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE 804 EAST GATE DRIVE, SUITE 200, MOUNT LAUREL, NJ 08054 FOR IMMEDIATE RELEASE InTest Reports Preliminary Second Quarter 2026 Results • Second Quarter Revenue Estimated to be Approximately $35 Million • Second Quarter Gross Margin Estimated to be Approxima

$ELVRMed

Elevra Lithium Ltd (ASX:ELV) Corporate Presentation - Outlines Growth Strategy for North American Lithium Platform

Elevra Lithium Ltd (ASX:ELV) outlined its growth strategy for North American Lithium (NAL) in Quebec, targeting 373,000 tonnes of spodumene concentrate annually. FY26 production was 197,967 tonnes, with revenue of US$202 million. The company plans a three-stage expansion, with initial capital expenditure of US$271 million. FY27 production guidance is 198,000 to 210,000 tonnes.

$CVXMedAI 8/10

Chevron (CVX) Doubles Down on Venezuela with a $7 Billion Oil Bet

Chevron (CVX) plans to invest $7 billion in Venezuela over five years to double oil production to 600,000 barrels per day, adding areas in the Orinoco Belt to its joint venture with PDVSA. The move leverages Chevron's existing presence and aims for low-cost growth, despite political and regulatory risks. Venezuela holds the world's largest crude oil reserves but faces infrastructure challenges.